Compare ABM & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABM | BEAM |
|---|---|---|
| Founded | 1909 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | ABM | BEAM |
|---|---|---|
| Price | $47.58 | $26.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $51.50 | $46.00 |
| AVG Volume (30 Days) | 677.8K | ★ 2.1M |
| Earning Date | 03-11-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | ★ 102.34 | N/A |
| EPS | ★ 2.59 | N/A |
| Revenue | ★ $8,745,900,000.00 | $55,701,000.00 |
| Revenue This Year | $5.71 | N/A |
| Revenue Next Year | $1.99 | $22.06 |
| P/E Ratio | $18.19 | ★ N/A |
| Revenue Growth | ★ 4.62 | N/A |
| 52 Week Low | $40.00 | $13.53 |
| 52 Week High | $54.90 | $36.44 |
| Indicator | ABM | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 64.63 | 41.22 |
| Support Level | $45.25 | $24.30 |
| Resistance Level | $46.60 | $29.26 |
| Average True Range (ATR) | 0.95 | 2.12 |
| MACD | 0.17 | -0.80 |
| Stochastic Oscillator | 100.00 | 15.40 |
ABM Industries Inc is a provider of integrated facility solutions. It offers its solutions through five segments: Business and Industry, Manufacturing and Distribution, Education, Aviation and Technical solutions. The company derives the majority of its revenue from the business and industry segment, which encompasses janitorial, facilities engineering, and parking services for commercial real estate properties and sports and entertainment venues, hospitals, as well as vehicle maintenance and other services to rental car providers. The company mainly operates in the United States of America.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.